Galmed Pharmaceuticals Ltd. (GLMD) Stock Price

GLMDStock

$4.31−66.02%52W

Market Cap$4.48M

P/E—

PEG Ratio—

Div yield—

Beta0.60

GLMD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-25.08%

Price vs S&P 500 (4W)-8.20%

VGM Score55.01

Book Value / Share (Quarterly)$2.11

P/TBV (Annual)0.09x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.16

Price vs S&P 500 (YTD)-44.46%

Net Profit Margin (TTM)-424.24%

EPS (TTM)$-2.07

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$-2.07

EPS (Annual)$-8.09

ROI (Annual)-46.06%

Net Profit Margin (5Y Avg)-5369.04%

Cash / Share (Quarterly)$1.42

ROA (Last FY)-40.65%

EBITD / Share (TTM)$-2.14

ROE (5Y Avg)-80.13%

Operating Margin (TTM)-439.83%

Cash Flow / Share (Annual)$-0.96

P/B Ratio0.31x

P/B Ratio (Quarterly)0.23x

Net Income / Employee (Annual)$-2,506,700

EV / Revenue (TTM)1.21x

Net Interest Coverage (TTM)-93.05x

ROA (TTM)-56.15%

EPS Incl Extra (Annual)$-8.09

Current Ratio (Annual)6.55x

Quick Ratio (Quarterly)7.71x

3-Month Avg Trading Volume0.08M

52-Week Price Return-66.02%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$6.28

P/S Ratio (Annual)2.15x

Asset Turnover (Annual)0.02x

52-Week High$13.20

Operating Margin (5Y Avg)-5585.52%

EPS Excl Extra (Annual)$-8.09

Tangible BV CAGR (5Y)-3.20%

26-Week Price Return-13.83%

Quick Ratio (Annual)6.45x

13-Week Price Return-12.72%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.71x

Enterprise Value$2.79M

Asset Turnover (TTM)0.04x

Book Value / Share Growth (5Y)-40.10%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-479.41%

Cash / Share (Annual)$1.67

3-Month Return Std Dev110.14%

Net Income / Employee (TTM)$-3,705,000

ROE (Last FY)-46.06%

Net Interest Coverage (Annual)-6.64x

EPS Basic Excl Extra (Annual)$-8.09

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.07

ROI (TTM)-64.10%

P/S Ratio (TTM)1.90x

Pretax Margin (5Y Avg)-5365.36%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$7.99

Price vs S&P 500 (52W)-84.33%

Year-to-Date Return-32.50%

5-Day Price Return-9.60%

EPS Normalized (Annual)$-8.09

ROA (5Y Avg)-66.75%

Net Profit Margin (Annual)-483.33%

Month-to-Date Return-18.51%

Cash Flow / Share (TTM)$-6.77

EBITD / Share (Annual)$-7.89

Operating Margin (Annual)-525.49%

ROI (5Y Avg)-80.13%

EPS Basic Excl Extra (TTM)$-2.07

P/TBV (Quarterly)0.12x

P/B Ratio (Annual)0.26x

Pretax Margin (TTM)-420.78%

Book Value / Share (Annual)$2.40

Price vs S&P 500 (13W)-15.51%

Beta0.60x

Revenue / Share (TTM)$0.00

ROE (TTM)-64.10%

52-Week Low$3.29

vGradeA

mGradeD

vgmGradeC

GLMD Earnings Surprise History

Q2 25-5.04est. -6.64

Q3 25-2.64est. -4.32

Q4 25-7.36est. -4.08

Q1 26-2.32est. -3.04

GLMD Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

2.17

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
GLMDGalmed Pharmaceuticals Ltd.	A	—	D	$4.31
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals is a biopharmaceutical company developing Aramchol, a novel therapeutic candidate for liver disease. The company previously focused Aramchol on non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), as well as other fibro-inflammatory conditions. Galmed is now advancing development of Aramchol for oncological applications, representing a strategic expansion of the program's potential therapeutic uses.